1
|
Shen S, Wang S, Zhou D, Wu X, Gao M, Wu J, Yang Y, Pan X, Wang N. A clinician's perspective on boron neutron capture therapy: promising advances, ongoing trials, and future outlook. Int J Radiat Biol 2024; 100:1126-1142. [PMID: 38986056 DOI: 10.1080/09553002.2024.2373746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 05/15/2024] [Accepted: 06/13/2024] [Indexed: 07/12/2024]
Abstract
PURPOSE This comprehensive review aims to provide a unique clinical perspective on the latest advances and ongoing boron neutron capture therapy (BNCT) trials for various cancers. METHODS We critically analyzed clinical data from BNCT trials for head and neck cancer, glioblastoma, melanoma, meningioma, breast cancer, and liver tumors. We investigated differences in tumor responses and normal tissue toxicities among trials and discussed potential contributing factors. We also identified the limitations of early BNCT trials and proposed strategies to optimize future trial design. RESULTS BNCT has shown promising results in treating head and neck cancer, with high response rates and improved survival in patients with recurrent disease. In glioblastoma, BNCT combined with surgery and chemotherapy has demonstrated survival benefits compared to standard treatments. BNCT has also been successfully used for recurrent high-grade meningiomas and shows potential for melanomas, extramammary Paget's disease, and liver tumors. However, differences in tumor responses and toxicities were observed among trials, potentially attributable to variations in treatment protocols, patient characteristics, and evaluation methods. CONCLUSIONS BNCT is a promising targeted radiotherapy for various cancers. Further optimization and well-designed randomized controlled trials are needed to establish its efficacy and safety. Future studies should focus on standardizing treatment protocols and addressing limitations to guide clinical decision-making and research priorities.
Collapse
Affiliation(s)
- Shumin Shen
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Shanghu Wang
- Department of Radiotherapy, Anhui Chest Hospital, Hefei, China
| | - Dachen Zhou
- Department of General Surgery, The Second Hospital of Anhui Medical University, Hefei, China
| | - Xiuwei Wu
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Mingzhu Gao
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Jinjin Wu
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Yucai Yang
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| | - Xiaoxi Pan
- Department of Nuclear Medicine, The Second Hospital of Anhui Medical University, Hefei, China
| | - Nianfei Wang
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China
| |
Collapse
|
2
|
Tokura D, Konarita K, Suzuki M, Ogata K, Honda Y, Miura Y, Nishiyama N, Nomoto T. Active control of pharmacokinetics using light-responsive polymer-drug conjugates for boron neutron capture therapy. J Control Release 2024; 371:445-454. [PMID: 38844180 DOI: 10.1016/j.jconrel.2024.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 05/03/2024] [Accepted: 06/03/2024] [Indexed: 06/11/2024]
Abstract
In boron neutron capture therapy (BNCT), boron drugs should exhibit high intratumoral boron concentrations during neutron irradiation, while being cleared from the blood and normal organs. However, it is usually challenging to achieve such tumor accumulation and quick clearance simultaneously in a temporally controlled manner. Here, we developed a polymer-drug conjugate that can actively control the clearance of the drugs from the blood. This polymer-drug conjugate is based on a biocompatible polymer that passively accumulates in tumors. Its side chains were conjugated with the low-molecular-weight boron drugs, which are immediately excreted by the kidneys, via photolabile linkers. In a murine subcutaneous tumor model, the polymer-drug conjugate could accumulate in the tumor with the high boron concentration ratio of the tumor to the surrounding normal tissue (∼10) after intravenous injection while a considerable amount remained in the bloodstream as well. Photoirradiation to blood vessels through the skin surface cleaved the linker to release the boron drug in the blood, allowing for its rapid clearance from the bloodstream. Meanwhile, the boron concentration in the tumor which was not photoirradiated could be maintained high, permitting strong BNCT effects. In clinical BNCT, the dose of thermal neutrons to solid tumors is determined by the maximum radiation exposure to normal organs. Thus, our polymer-drug conjugate may enable us to increase the therapeutic radiation dose to tumors in such a practical situation.
Collapse
Affiliation(s)
- Daiki Tokura
- Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Kakeru Konarita
- Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Minoru Suzuki
- Division of Particle Radiation Oncology, Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Keisuke Ogata
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Yuto Honda
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Yutaka Miura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Nobuhiro Nishiyama
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Takahiro Nomoto
- Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan; Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan.
| |
Collapse
|
3
|
Lan G, Song Q, Luan Y, Cheng Y. Targeted strategies to deliver boron agents across the blood-brain barrier for neutron capture therapy of brain tumors. Int J Pharm 2024; 650:123747. [PMID: 38151104 DOI: 10.1016/j.ijpharm.2023.123747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/21/2023] [Accepted: 12/23/2023] [Indexed: 12/29/2023]
Abstract
Boron neutron capture therapy (BNCT), as an innovative radiotherapy technology, has demonstrated remarkable outcomes when compared to conventional treatments in the management of recurrent and refractory brain tumors. However, in BNCT of brain tumors, the blood-brain barrier is a main stumbling block for restricting the transport of boron drugs to brain tumors, while the tumor targeting and retention of boron drugs also affect the BNCT effect. This review focuses on the recent development of strategies for delivering boron drugs crossing the blood-brain barrier and targeting brain tumors, providing new insights for the development of efficient boron drugs for the treatment of brain tumors.
Collapse
Affiliation(s)
- Gongde Lan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Qingxu Song
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China
| | - Yuxia Luan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Yufeng Cheng
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
| |
Collapse
|
4
|
Okada S, Nishimura K, Ainaya Q, Shiraishi K, Anufriev SA, Sivaev IB, Sakurai Y, Suzuki M, Yokoyama M, Nakamura H. Development of a Gadolinium-Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy. Mol Pharm 2023; 20:6311-6318. [PMID: 37909734 DOI: 10.1021/acs.molpharmaceut.3c00726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
Noninvasive monitoring of boron agent biodistribution is required in advance of neutron capture therapy. In this study, we developed a gadolinium-boron-conjugated albumin (Gd-MID-BSA) for MRI-guided neutron capture therapy. Gd-MID-BSA was prepared by labeling bovine serum albumin with a maleimide-functionalized gadolinium complex and a maleimide-functionalized closo-dodecaborate orthogonally. The accumulation of Gd-MID-BSA in tumors in CT26 tumor-bearing mice reached a maximum at 24 h after the injection, as confirmed by T1-based MRI and biodistribution analysis using inductively coupled plasma optical emission spectrometry. The concentrations of boron and gadolinium in the tumors exceeded the thresholds required for boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT), respectively. The boron concentration ratios of tumor to blood and tumor to normal tissues satisfied the clinical criteria, indicating the reduction of undesired nuclear reactions of endogenous nuclei. The molar ratio of boron to gadolinium in the tumor was close to that of Gd-MID-BSA, demonstrating that the accumulation of Gd-MID-BSA in the tumor can be evaluated by MRI. Thermal neutron irradiation with Gd-MID-BSA resulted in significant suppression of tumor growth compared to the group injected with a boron-conjugated albumin without gadolinium (MID-BSA). The neutron irradiation with Gd-MID-BSA did not cause apparent side effects. These results demonstrate that the conjugation of gadolinium and boron within the albumin molecule offers a novel strategy for enhancing the therapeutic effect of BNCT and the potential of MRI-guided neutron capture therapy as a promising treatment for malignant tumors.
Collapse
Affiliation(s)
- Satoshi Okada
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Kai Nishimura
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Qarri Ainaya
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| | - Kouichi Shiraishi
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan
| | - Sergey A Anufriev
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119334 Moscow, Russia
| | - Igor B Sivaev
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119334 Moscow, Russia
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka 590-0494, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka 590-0494, Japan
| | - Masayuki Yokoyama
- Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan
| |
Collapse
|
5
|
Luo T, Huang W, Chu F, Zhu T, Feng B, Huang S, Hou J, Zhu L, Zhu S, Zeng W. The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy. Mol Pharm 2023; 20:4942-4970. [PMID: 37728998 DOI: 10.1021/acs.molpharmaceut.3c00701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/22/2023]
Abstract
Cancer is widely recognized as one of the most devastating diseases, necessitating the development of intelligent diagnostic techniques, targeted treatments, and early prognosis evaluation to ensure effective and personalized therapy. Conventional treatments, unfortunately, suffer from limitations and an increased risk of severe complications. In light of these challenges, boron neutron capture therapy (BNCT) has emerged as a promising approach for cancer treatment with unprecedented precision to selectively eliminate tumor cells. The distinctive and promising characteristics of BNCT hold the potential to revolutionize the field of oncology. However, the clinical application and advancement of BNCT technology face significant hindrance due to the inherent flaws and limited availability of current clinical drugs, which pose substantial obstacles to the practical implementation and continued progress of BNCT. Consequently, there is an urgent need to develop efficient boron agents with higher boron content and specific tumor-targeting properties. Researchers aim to address this need by integrating tumor-targeting strategies with BNCT, with the ultimate goal of establishing BNCT as an effective, readily available, and cutting-edge treatment modality for cancer. This review delves into the recent advancements in integrating tumor-targeting strategies with BNCT, focusing on the progress made in developing boron agents specifically designed for BNCT. By exploring the current state of BNCT and emphasizing the prospects of tumor-targeting boron agents, this review provides a comprehensive overview of the advancements in BNCT and highlights its potential as a transformative treatment option for cancer.
Collapse
Affiliation(s)
- Ting Luo
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Wenzhi Huang
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Feiyi Chu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Tianyu Zhu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Bin Feng
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Shuai Huang
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Jing Hou
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| | - Liyong Zhu
- The Third Xiangya Hospital, Central South University, Changsha 410013, China
| | - Shaihong Zhu
- The Third Xiangya Hospital, Central South University, Changsha 410013, China
| | - Wenbin Zeng
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha 410013, China
| |
Collapse
|
6
|
Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using Gd 10B 6 Nanoparticles under MRI/CT Image Guidance. JACS AU 2023; 3:2192-2205. [PMID: 37654578 PMCID: PMC10466345 DOI: 10.1021/jacsau.3c00250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 07/16/2023] [Accepted: 07/26/2023] [Indexed: 09/02/2023]
Abstract
Eradication of head-and-neck (H&N) tumors is very difficult and challenging because of the characteristic feature of frequent recurrence and the difficulty in killing cancer stem cells. Neutron capture therapy (NCT) is emerging as a noninvasive potential modality for treatments of various types of tumors. Herein, we report that 98.5% 10B-enriched anti-EGFR-Gd10B6 nanoparticles can not only deliver large doses of 158 μg 10B/g tumor tissues as well as 56.8 μg 157Gd/g tumor tissues with a very high tumor-to-blood (T/B) 10B ratio of 4.18, but also exert very effective CT/MRI image-guided combined GdBNCT effects on killing cancer stem cells and eradication of recurrent head-and-neck (H&N) tumors. This leads to a long average half-lifespan of 81 days for H&N tumor-bearing mice, which is a record-making result, and surpasses the best result reported in the literature using combined radiotherapy and T cell-mediated immunotherapy (70 d).
Collapse
Affiliation(s)
- Munusamy Shanmugam
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Naresh Kuthala
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| | - Xiangyi Kong
- Department
of Breast Surgical Oncology, National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Chi-Shiun Chiang
- Department
of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan R.O.C.
| | - Kuo Chu Hwang
- Department
of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan ROC
| |
Collapse
|
7
|
Caminade AM, Milewski M, Hey-Hawkins E. Dendritic Structures Functionalized with Boron Clusters, in Particular Carboranes, and Their Biological Properties. Pharmaceutics 2023; 15:2117. [PMID: 37631334 PMCID: PMC10459656 DOI: 10.3390/pharmaceutics15082117] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 07/28/2023] [Accepted: 08/04/2023] [Indexed: 08/27/2023] Open
Abstract
The presence of a large number of boron atoms in boron clusters make them attractive tools for the treatment of cancer using boron neutron capture therapy (BNCT). Since the quantity of boron atoms present in the target cell directly affects the effectiveness of BNCT, the idea of gathering a high number of boron atoms in a single entity has emerged many years ago. In this perspective, using hyper-branched macromolecules such as dendrimers appears as an interesting solution. In this review, we will first present the synthesis of diverse dendritic entities (dendrimers, dendrons, and Janus dendrimers) that incorporate boron clusters, in particular carboranes, anywhere in their structure. Four parts of this review present the synthesis of dendrimers having boron clusters on the surface, or inside their structure, of dendrons and of Janus dendrimers, bearing boron clusters. Practically all these boronated dendritic structures were synthesized with the objective to study their biological properties, but in fact only a few of them have been tested against cancerous cells, and even a smaller number was tested in BNCT experiments. The biological experiments are discussed in the fifth part of this review. A good efficiency is generally observed with the boronated dendrimers, even in animal models, with an increase in their mean survival time (MST).
Collapse
Affiliation(s)
- Anne-Marie Caminade
- Laboratoire de Chimie de Coordination (LCC-CNRS) 205 Route de Narbonne, CEDEX 4, 31077 Toulouse, France;
- LCC-CNRS, Université de Toulouse, CNRS, 31077 Toulouse, France
| | - Max Milewski
- Laboratoire de Chimie de Coordination (LCC-CNRS) 205 Route de Narbonne, CEDEX 4, 31077 Toulouse, France;
- LCC-CNRS, Université de Toulouse, CNRS, 31077 Toulouse, France
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany;
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany;
| |
Collapse
|
8
|
Matović J, Bahrami K, Stockmann P, Sokka IK, Khng YC, Sarparanta M, Hey-Hawkins E, Rautio J, Ekholm FS. Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy. Mol Pharm 2023. [PMID: 37134022 DOI: 10.1021/acs.molpharmaceut.3c00119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Boron neutron capture therapy (BNCT) is a cancer therapy in which boron delivery agents play a crucial role. In theory, delivery agents with high tumor targeting capabilities can lead to selective eradication of tumor cells without causing harmful side effects. We have been working on a GLUT1-targeting strategy to BNCT for a number of years and found multiple promising hit compounds which outperform the clinically employed boron delivery agents in vitro. Herein, we continue our work in the field by further diversification of the carbohydrate scaffold in order to map the optimal stereochemistry of the carbohydrate core. In the sweet battle of the epimers, carborane-bearing d-galactose, d-mannose, and d-allose are synthesized and subjected to in vitro profiling studies─with earlier work on d-glucose serving as the reference. We find that all of the monosaccharide delivery agents display a significantly improved boron delivery capacity over the delivery agents approved for clinical use in vitro, thus providing a sound foundation for advancing toward in vivo preclinical assessment studies.
Collapse
Affiliation(s)
- Jelena Matović
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Katayun Bahrami
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Philipp Stockmann
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Iris K Sokka
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - You Cheng Khng
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Mirkka Sarparanta
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig D-04103, Germany
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland
| | - Filip S Ekholm
- Department of Chemistry, University of Helsinki, Finland, P.O. Box 55, Helsinki FI-00014, Finland
| |
Collapse
|
9
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
10
|
Terada S, Tsunetoh S, Tanaka Y, Tanaka T, Kashiwagi H, Takata T, Kawabata S, Suzuki M, Ohmichi M. Boron uptake of boronophenylalanine and the effect of boron neutron capture therapy in cervical cancer cells. Appl Radiat Isot 2023; 197:110792. [PMID: 37062147 DOI: 10.1016/j.apradiso.2023.110792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 06/13/2022] [Accepted: 03/26/2023] [Indexed: 04/05/2023]
Abstract
There are few studies about boron neutron capture therapy (BNCT) for cervical cancer. The present study evaluated the biodistribution of boronophenylalanine (BPA) and the effect of BNCT on cervical cancer cell lines. BPA exposure and neutron irradiation of cervical cancer cell lines resulted in decreased survival fraction compared to irradiation only. In vivo cervical cancer tumor boron concentration was highest at 2.5 h after BPA intraperitoneal administration, and higher than in the other organs. BNCT may be effective against cervical carcinoma.
Collapse
|
11
|
Chan WJ, Bupphathong S, Cho HL, Goudar VS, Dehestani S, Chiang CS, Tseng FG. Engineering a potent boron-10-enriched polymeric nanoparticle for boron neutron capture therapy. Nanomedicine (Lond) 2023; 18:743-754. [PMID: 37306216 DOI: 10.2217/nnm-2022-0330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Background: Boron neutron capture therapy (BNCT) is a promising cancer treatment that eliminates tumor cells by triggering high-energy radiation within cancer cells. Aim: In vivo evaluation of poly(vinyl alcohol)/boric acid crosslinked nanoparticles (PVA/BA NPs) for BNCT. Materials & methods: PVA/BA NPs were synthesized and intravenously injected into tumor-bearing mice for BNCT. Results: The in vitro boron uptake of PVA/BA NPs in tumor cells was 70-fold higher than the required boron uptake for successful BNCT. In an in vivo study, PVA/BA NPs showed a 44.29% reduction in tumor size compared with clinically used boronophenylalanine for oral cancer in a murine model. Conclusion: PVA/BA NPs exhibited effective therapeutic results for oral cancer treatments in BNCT.
Collapse
Affiliation(s)
- Wei-Jen Chan
- Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Sasinan Bupphathong
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| | - Han-Lin Cho
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| | | | - Sina Dehestani
- Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Chi-Shiun Chiang
- Department of Biomedical Engineering & Environmental Sciences, National Tsing Hua University, Hsinchu City, 30013, Taiwan
| | - Fan-Gang Tseng
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| |
Collapse
|
12
|
Goel M, Mackeyev Y, Krishnan S. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts. Cancer Nanotechnol 2023; 14:15. [PMID: 36865684 PMCID: PMC9968708 DOI: 10.1186/s12645-023-00165-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 02/13/2023] [Indexed: 03/01/2023] Open
Abstract
In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora of applications in biology and medicine. A convergence of these disciplines has emerged more recently with the advent of nanotechnology-aided radiopharmaceuticals. Capitalizing on the unique physical and functional properties of nanoparticles, radiolabeled nanomaterials or nano-radiopharmaceuticals have the potential to enhance imaging and therapy of human diseases. This article provides an overview of various radionuclides used in diagnostic, therapeutic, and theranostic applications, radionuclide production through different techniques, conventional radionuclide delivery systems, and advancements in the delivery systems for nanomaterials. The review also provides insights into fundamental concepts necessary to improve currently available radionuclide agents and formulate new nano-radiopharmaceuticals.
Collapse
Affiliation(s)
- Muskan Goel
- Amity School of Applied Sciences, Amity University, Gurugram, Haryana 122413 India
| | - Yuri Mackeyev
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA
| | - Sunil Krishnan
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA
| |
Collapse
|
13
|
Ailuno G, Balboni A, Caviglioli G, Lai F, Barbieri F, Dellacasagrande I, Florio T, Baldassari S. Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment. Cells 2022; 11:cells11244029. [PMID: 36552793 PMCID: PMC9776957 DOI: 10.3390/cells11244029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 12/09/2022] [Accepted: 12/11/2022] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine-fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.
Collapse
Affiliation(s)
- Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Alice Balboni
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| | | | - Francesco Lai
- Department of Life and Environmental Sciences (DiSVA), University of Cagliari, 09124 Cagliari, Italy
| | - Federica Barbieri
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
| | | | - Tullio Florio
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
- IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Sara Baldassari
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| |
Collapse
|
14
|
Roy I, Krishnan S, Kabashin AV, Zavestovskaya IN, Prasad PN. Transforming Nuclear Medicine with Nanoradiopharmaceuticals. ACS NANO 2022; 16:5036-5061. [PMID: 35294165 DOI: 10.1021/acsnano.1c10550] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Nuclear medicine is expected to make major advances in cancer diagnosis and therapy; tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal damage to healthy tissues. The current scope of nuclear medicine can be significantly expanded by integration with nanomedicine, which utilizes nanoparticles for cancer diagnosis and therapy by capitalizing on the increased surface area-to-volume ratio, the passive/active targeting ability and high loading capacity, the greater interaction cross section with biological tissues, the rich surface properties of nanomaterials, the facile decoration of nanomaterials with a plethora of functionalities, and the potential for multiplexing several functionalities within one construct. This review provides a comprehensive discussion of nuclear nanomedicine using tumor-targeted nanoparticles for cancer radiation therapy with either pre-embedded radionuclides or nonradioactive materials which can be extrinsically triggered using various external nuclear particle sources to produce in situ radioactivity. In addition, it describes the prospect of combining nuclear nanomedicine with other modalities to enable synergistically enhanced combination therapies. The review also discusses advances in the fabrication of radionuclides as well as describes laser ablation technologies for producing nanoradiopharmaceuticals, which combine the ease of production with exceptional purity and rapid biodegradability, along with additional imaging or therapeutic functionalities. From a practical standpoint, these attributes of nanoradiopharmaceuticals may provide distinct advantages in diagnostic/therapeutic sensitivity and specificity, imaging resolution, and scalability of turnkey platforms. Coupling image-guided targeted radiation therapy with the possibility of in situ activation of nanomaterials as well as combining with other therapeutic modalities using a multifunctional nanoplatform could herald an era of exciting technological and therapeutic advances to radically transform the landscape of nuclear medicine. The review concludes with a discussion of current challenges and presents the authors' views on future opportunities to stimulate further research in this rewarding field of high societal impact.
Collapse
Affiliation(s)
- Indrajit Roy
- Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Sunil Krishnan
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, Florida 32224, United States
| | - Andrei V Kabashin
- Aix Marseille University, CNRS, LP3, Campus de Luminy - Case 917, 13288 Marseille, France
- MEPhI, Institute of Engineering Physics for Biomedicine (PhysBio), 115409 Moscow, Russia
| | - Irina N Zavestovskaya
- MEPhI, Institute of Engineering Physics for Biomedicine (PhysBio), 115409 Moscow, Russia
- Nuclear Physics and Astrophysics Department, LPI of RAS, 119991 Moscow, Russia
| | - Paras N Prasad
- MEPhI, Institute of Engineering Physics for Biomedicine (PhysBio), 115409 Moscow, Russia
- Department of Chemistry and Institute for Lasers, Photonics, and Biophotonics, University at Buffalo, The State University of New York, Buffalo, New York 14260, United States
| |
Collapse
|
15
|
Wang S, Zhang Z, Miao L, Li Y. Boron Neutron Capture Therapy: Current Status and Challenges. Front Oncol 2022; 12:788770. [PMID: 35433432 PMCID: PMC9009440 DOI: 10.3389/fonc.2022.788770] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 03/04/2022] [Indexed: 11/13/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a re-emerging therapy with the ability to selectively kill tumor cells. After the boron delivery agents enter the tumor tissue and enrich the tumor cells, the thermal neutrons trigger the fission of the boron atoms, leading to the release of boron atoms and then leading to the release of the α particles (4He) and recoil lithium particles (7Li), along with the production of large amounts of energy in the narrow region. With the advantages of targeted therapy and low toxicity, BNCT has become a unique method in the field of radiotherapy. Since the beginning of the last century, BNCT has been emerging worldwide and gradually developed into a technology for the treatment of glioblastoma multiforme, head and neck cancer, malignant melanoma, and other cancers. At present, how to develop and innovate more efficient boron delivery agents and establish a more accurate boron-dose measurement system have become the problem faced by the development of BNCT. We discuss the use of boron delivery agents over the past several decades and the corresponding clinical trials and preclinical outcomes. Furthermore, the discussion brings recommendations on the future of boron delivery agents and this therapy.
Collapse
Affiliation(s)
- Song Wang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Zhengchao Zhang
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Lele Miao
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| | - Yumin Li
- Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.,Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, China
| |
Collapse
|
16
|
Soleimanbeigi M, Dousti F, Hassanzadeh F, Mirian M, Varshosaz J, Kasesaz Y, Rostami M. Boron Phenyl Alanine Targeted Chitosan-PNIPAAm Core-Shell Thermo-Responsive Nanoparticles; Boosting Drug Delivery to Glioblastoma in BNCT. Drug Dev Ind Pharm 2022; 47:1607-1623. [DOI: 10.1080/03639045.2022.2032132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Monireh Soleimanbeigi
- Master Student of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fatemeh Dousti
- Master Student of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Farshid Hassanzadeh
- Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mina Mirian
- Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Science, Isfahan, Iran
| | - Jaleh Varshosaz
- Novel Drug Delivery Systems Research Centre and Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Science, Isfahan, Iran
| | - Yaser Kasesaz
- Reactor and Nuclear Safety Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
| | - Mahboubeh Rostami
- Novel Drug Delivery Systems Research Centre and Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
17
|
Ueda H, Suzuki M, Sakurai Y, Tanaka T, Aoki S. Design, Synthesis and Biological Evaluation of Boron‐Containing Macrocyclic Polyamine Dimers and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. Eur J Inorg Chem 2022. [DOI: 10.1002/ejic.202100949] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Science and Technology Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Biomedical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| |
Collapse
|
18
|
Tojo T, Niiuchi A, Kondo T, Yuasa M. Evaluation of the Correlation between Porphyrin Accumulation in Cancer Cells and Functional Porphyrin Positions of the Phenyl Group. ChemMedChem 2021; 17:e202100636. [PMID: 34859953 DOI: 10.1002/cmdc.202100636] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 12/01/2021] [Indexed: 01/26/2023]
Abstract
Porphyrin selectively shows tumour accumulation and has attracted attention as a carrier molecule for drug delivery systems (DDS). Porphyrin has two functional sites termed the meso- and β-positions. In previous work, meso-porphyrin derivatives with an alkyl group were found to exhibit greater accumulation in human breast cancer cells (MCF-7). To identify the correlation between porphyrin accumulation and functional porphyrin positions of other functional groups, the accumulation of porphyrin derivatives with a phenyl group was investigated. The β-porphyrin derivative with a phenyl group showed higher accumulation in MCF-7 cells and greater affinity for albumin than the meso-porphyrin derivative. The results of density functional theory (DFT) calculations suggest that the β-porphyrin derivative with a phenyl group had higher planarity across the total structure than the meso-porphyrin derivative. It was concluded that the greater planarity of the β-porphyrin derivative with a phenyl group might lead to superior MCF-7 cell accumulation.
Collapse
Affiliation(s)
- Toshifumi Tojo
- Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan
| | - Ayano Niiuchi
- Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan
| | - Takeshi Kondo
- Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan.,Research Institute for Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan
| | - Makoto Yuasa
- Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan.,Research Institute for Science and Technology, Tokyo University of Science, Yamazaki, Noda-shi, Chiba, 278-8510, Japan
| |
Collapse
|
19
|
Li F, Luo Z. Boron delivery agents for boron neutron capture therapy. CHINESE SCIENCE BULLETIN-CHINESE 2021. [DOI: 10.1360/tb-2021-1013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Popova T, Dymova MA, Koroleva LS, Zakharova OD, Lisitskiy VA, Raskolupova VI, Sycheva T, Taskaev S, Silnikov VN, Godovikova TS. Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy. Molecules 2021; 26:molecules26216537. [PMID: 34770947 PMCID: PMC8586956 DOI: 10.3390/molecules26216537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 10/21/2021] [Accepted: 10/27/2021] [Indexed: 11/16/2022] Open
Abstract
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)-a carrier protein with a long plasma half-life-is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-'click' chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Collapse
Affiliation(s)
- Tatyana Popova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Maya A Dymova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Ludmila S Koroleva
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Olga D Zakharova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Vladimir A Lisitskiy
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Valeria I Raskolupova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Tatiana Sycheva
- Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia
| | - Sergei Taskaev
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
- Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia
| | - Vladimir N Silnikov
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
| | - Tatyana S Godovikova
- Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| |
Collapse
|
21
|
Yao Q, Wu C, Chen J, Zhao Y, Gao Y. Enzyme-instructed supramolecular assemblies promote intracellular boron accumulation for boron neutron capture therapy. NANOTECHNOLOGY 2021; 32:435602. [PMID: 34280913 DOI: 10.1088/1361-6528/ac15ca] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 07/19/2021] [Indexed: 06/13/2023]
Abstract
Selective accumulation of boron agents in cancer cells is of critical importance for BNCT. Here we involve enzyme-instructed supramolecular assembly (EISA) to facilitate the accumulation of a typical boron agent borylphenylalanine (BPA) in cancer cells. By covalently conjugating BPA to the phosphorylated assembly precursor, the boron-bearing precursors undergo phosphatase-catalyzed dephosphorylation to yield assembly molecules, which then self-assemble to form nanomaterials. Due to the up-regulated phosphatase activity of cancer cells, kinetic preference allows the EISA to accumulate boron in HeLa cells selectively. Interestingly, by attaching BPA on the backbone or side-chain of precursor, the boron-bearing isomers show different assembly propensity with time-dependent morphology change, which leads to the differentiated accumulation of boron inside cells. Overall, the optimized boron-bearing assembly precursor could significantly improve the boron accumulation compared with BPA in cancer cells. In this study, we have demonstrated a convenient method to introduce boron agents to cancer cells. We envision that the EISA-mediated accumulation of boron will be helpful in the design of boron agents to facilitate BNCT treatment.
Collapse
Affiliation(s)
- Qingxin Yao
- CAS Center of Excellence for Nanoscience, Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| | - Chengling Wu
- CAS Center of Excellence for Nanoscience, Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
| | - Jiali Chen
- CAS Center of Excellence for Nanoscience, Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
| | - Yan Zhao
- CAS Center of Excellence for Nanoscience, Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
| | - Yuan Gao
- CAS Center of Excellence for Nanoscience, Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
- University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
| |
Collapse
|
22
|
Chan WJ, Tseng FG. Nanomedicine in boron neutron capture therapy for cancer treatment: opportunities, challenges and future perspectives. Nanomedicine (Lond) 2021; 16:1631-1634. [PMID: 34264135 DOI: 10.2217/nnm-2021-0082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Wei-Jen Chan
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan
| | - Fan-Gang Tseng
- Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, Taiwan.,Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu, 30013, Taiwan.,Research Center for Applied Sciences, Academia Sinica, Taipei, 11529, Taiwan
| |
Collapse
|
23
|
Strominger AM, Sutherland BL, Flemming AS, Dutmer BC, Gilbert TM. Additivity of Diene Substituent Gibbs Free Energy Contributions for Diels-Alder Reactions between (F 3C) 2B = NMe 2 and Substituted Cyclopentadienes. J Phys Chem A 2021; 125:5456-5469. [PMID: 34110819 DOI: 10.1021/acs.jpca.1c02880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Systematic computational studies of pericyclic Diels-Alder-type reactions between aminoborane (F3C)2B = N(CH3)2, 1, and all permutations of substituted cyclopentadienes c-C5R1R2R3R4R5aR5b (R = H, CH3, CF3, F) allow isolation of substitutional effects on Gibbs free energy barrier heights and reaction Gibbs free energies. The effects appear to be additive in all cases. Substitution at positions 5a and 5b always increases barriers and reaction energies, an effect explained by steric interactions between substituents and the aminoborane moiety. For cases R = CH3, regioselectivities differ from those expected from canonical organic chemistry predictions. Frontier molecular orbital calculations suggest this arises from the extreme polarization of the π interaction in 1. For cases R = CF3, the 2/3-substitution comparison accords with canon, but the 1/4-substitution comparison does not. This appears to arise from a combination of electronic and steric issues. For cases R = F, many of the reactions are exergonic, in contrast to the cases R = CH3, CF3. Additionally, fluorine substitution at positions 2 and 4 has a barrier-lowering effect. Frontier molecular orbital calculations support an orbital-based preference for formation of 2- and 4-substituted "meta" products rather than "ortho/para" products.
Collapse
Affiliation(s)
- Abbygale M Strominger
- Department of Chemistry, Highland Community College, Freeport, Illinois 61032, United States
| | - Brooke L Sutherland
- Department of Chemistry, Highland Community College, Freeport, Illinois 61032, United States
| | - Austin S Flemming
- Department of Chemistry, Highland Community College, Freeport, Illinois 61032, United States
| | - Brendan C Dutmer
- Department of Chemistry, Highland Community College, Freeport, Illinois 61032, United States
| | - Thomas M Gilbert
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois 60115, United States
| |
Collapse
|
24
|
Ueda H, Suzuki M, Kuroda R, Tanaka T, Aoki S. Design, Synthesis, and Biological Evaluation of Boron-Containing Macrocyclic Polyamines and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. J Med Chem 2021; 64:8523-8544. [PMID: 34077212 PMCID: PMC8279495 DOI: 10.1021/acs.jmedchem.1c00445] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Boron neutron capture therapy (BNCT)
is a binary therapeutic method
for cancer treatment based on the use of a combination of a cancer-specific
drug containing boron-10 (10B) and thermal neutron irradiation.
For successful BNCT, 10B-containing molecules need to accumulate
specifically in cancer cells, because destructive effect of the generated
heavy particles is limited basically to boron-containing cells. Herein,
we report on the design and synthesis of boron compounds that are
functionalized with 9-, 12-, and 15-membered macrocyclic polyamines
and their Zn2+ complexes. Their cytotoxicity, intracellular
uptake activity into cancer cells and normal cells, and BNCT effect
are also reported. The experimental data suggest that mono- and/or
diprotonated forms of metal-free [12]aneN4- and [15]aneN5-type ligands are uptaken into cancer cells, and their complexes
with intracellular metals such as Zn2+ would induce cell
death upon thermal neutron irradiation, possibly via interactions
with DNA.
Collapse
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-nishi, Kumatori, Osaka 590-0494, Japan
| | - Reiko Kuroda
- Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Biomedical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| |
Collapse
|
25
|
Quan H, Fan L, Huang Y, Xia X, He Y, Liu S, Yu J. Hyaluronic acid-decorated carborane-TAT conjugation nanomicelles: A potential boron agent with enhanced selectivity of tumor cellular uptake. Colloids Surf B Biointerfaces 2021; 204:111826. [PMID: 33984611 DOI: 10.1016/j.colsurfb.2021.111826] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/27/2021] [Accepted: 05/04/2021] [Indexed: 11/28/2022]
Abstract
Boron neutron capture therapy (BNCT) has received widespread attention as a new type of radiation therapy. The main problem encountered in BNCT is insufficient tumor cellular uptake of boron agents. In this study, cell-penetrating peptide TAT-conjugated o-carborane was synthesized. The conjugation can self-assemble to form positively charged carborane-TAT micelles, and then adsorb negatively charged hyaluronic acid (HA) to give core-shell structured carborane-TAT@HA micelles. Carborane-TAT@HA micelles exhibits a large amount of boron uptake at the tumor tissue through the enhanced permeability and retention (EPR) effect and the ability of HA to bind to CD44 receptors. Carborane-TAT@HA was wrapped by the HA shell during systemic circulation to avoid non-specific uptake of TAT with normal cells, while tumor microenvironment-responsive shedding of HA shell could expose Carborane-TAT to penetrate the cell membrane into tumor cells. Experiments have proved the enhanced selectivity of tumor cellular uptake of the boron drug, displayed excellent drug delivery potential, and can meet the basic requirements of BNCT.
Collapse
Affiliation(s)
- Hao Quan
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Li Fan
- Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, PR China
| | - Yushu Huang
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Xiaoyan Xia
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Yang He
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Shiyuan Liu
- Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, PR China.
| | - Jiahui Yu
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China.
| |
Collapse
|
26
|
Nomoto T, Yao Y, Inoue Y, Suzuki M, Kanamori K, Takemoto H, Matsui M, Tomoda K, Nishiyama N. Fructose-functionalized polymers to enhance therapeutic potential of p-boronophenylalanine for neutron capture therapy. J Control Release 2021; 332:184-193. [PMID: 33636247 DOI: 10.1016/j.jconrel.2021.02.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 02/17/2021] [Indexed: 11/24/2022]
Abstract
In boron neutron capture therapy (BNCT), boron drugs should accumulate selectively within a tumor and be quickly cleared from blood and normal organs. However, it is usually challenging to achieve the efficient tumor accumulation and the quick clearance simultaneously. Here we report the complex composed of a fructose-modified poly(ethylene glycol)-poly(l-lysine) block copolymer and p-boronophenylalanine, termed PEG-P[Lys/Lys(fructose)]-BPA, as a boron delivery system permitting selective accumulation within the target tumor with quick clearance from normal organs as well as blood. Our PEG-P[Lys/Lys(fructose)]-BPA could be internalized into tumor cells through LAT1 amino acid transporter-mediated endocytosis and retain in the targeted cells, thereby accomplishing more efficient accumulation and retention in a subcutaneous tumor than clinically used fructose-BPA complexes. Importantly, the moderately cationic property of the polymer facilitated renal clearance and PEG-P[Lys/Lys(fructose)]-BPA exhibited high accumulation contrast between the target tumor and the blood/normal organ. Finally, upon thermal neutron irradiation, PEG-P[Lys/Lys(fructose)]-BPA significantly inhibited the tumor growth in mice. PEG-P[Lys/Lys(fructose)]-BPA may be a promising boron delivery system for BNCT.
Collapse
Affiliation(s)
- Takahiro Nomoto
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan.
| | - Ying Yao
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Yukiya Inoue
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Minoru Suzuki
- Division of Particle Radiation Oncology, Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Kaito Kanamori
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Hiroyasu Takemoto
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Makoto Matsui
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Keishiro Tomoda
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Nobuhiro Nishiyama
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan; Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan.
| |
Collapse
|
27
|
Theranostics in Boron Neutron Capture Therapy. Life (Basel) 2021; 11:life11040330. [PMID: 33920126 PMCID: PMC8070338 DOI: 10.3390/life11040330] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.
Collapse
|
28
|
Gruzdev DA, Levit GL, Krasnov VP, Charushin VN. Carborane-containing amino acids and peptides: Synthesis, properties and applications. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213753] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
29
|
Telegina AA, Gruzdev DA, Levit GL, Krasnov VP. Synthesis of a novel planar-chiral nido-carborane amino acid. Russ Chem Bull 2021. [DOI: 10.1007/s11172-021-3121-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
30
|
Wróblewska A, Szermer-Olearnik B, Pajtasz-Piasecka E. Nanocząstki o wysokiej zawartości boru
jako potencjalne nośniki w terapii
borowo-neutronowej. POSTEP HIG MED DOSW 2021. [DOI: 10.5604/01.3001.0014.7760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Podstawą terapii borowo-neutronowej (boron neutron capture therapy, BNCT) jest selektywne
dostarczenie boru do komórek nowotworowych, a następnie napromienienie zmienionego
chorobowo miejsca wiązką neutronów. W wyniku tego procesu dochodzi do rozszczepienia
jądra izotopu 10B, co powoduje uwolnienie energii niszczącej komórki nowotworowe.
Mimo że badania związane z BNCT trwają od lat 50. XX wieku, pozostaje ona wciąż terapią
eksperymentalną. Jest to związane m.in. z brakiem nośników umożliwiających szybkie i skuteczne
wprowadzanie 10B do środowiska nowotworu. Tak więc często podnoszonym zagadnieniem
i jednym z głównych wyzwań dla rozwoju BNCT, jest poszukiwanie selektywnych
związków dostarczających wymaganą ilość tego pierwiastka. Istotnym aspektem są badania
nad nanometrycznymi strukturami, takimi jak liposomy zawierające związki bogate w bor
lub nieorganiczne nanocząstki – węglik boru czy azotek boru. Ze względu na dużą zawartość
boru oraz możliwość modyfikacji powierzchni tych nanocząstek, mogą się one okazać
wyjątkowo atrakcyjnym narzędziem w celowanej BNCT. Równie ważnym problemem tej terapii
jest opracowanie precyzyjnych powiązań między źródłem neutronów, specyfiką wiązki
a rodzajem zastosowanego nośnika. W artykule wskazujemy na wysoki potencjał związków
bogatych w bor jako nośników w celowanej terapii borowo-neutronowej.
Collapse
Affiliation(s)
- Anna Wróblewska
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Bożena Szermer-Olearnik
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Elżbieta Pajtasz-Piasecka
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| |
Collapse
|
31
|
Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier. Sci Rep 2021; 11:2046. [PMID: 33479459 PMCID: PMC7820339 DOI: 10.1038/s41598-021-81725-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 01/11/2021] [Indexed: 01/29/2023] Open
Abstract
Porphyrin derivatives accumulate selectively in cancer cells and are can be used as carriers of drugs. Until now, the substituents that bind to porphyrins (mainly at the meso-position) have been actively investigated, but the effect of the functional porphyrin positions (β-, meso-position) on tumor accumulation has not been investigated. Therefore, we investigated the correlation between the functional position of substituents and the accumulation of porphyrins in cancer cells using cancer cells. We found that the meso-derivative showed higher accumulation in cancer cells than the β-derivative, and porphyrins with less bulky substituent actively accumulate in cancer cells. When evaluating the intracellular distribution of porphyrin, we found that porphyrin was internalized by endocytosis and direct membrane permeation. As factors involved in these two permeation mechanisms, we evaluated the affinity between porphyrin-protein (endocytosis) and the permeability to the phospholipid bilayer membrane (direct membrane permeation). We found that the binding position of porphyrin affects the factors involved in the transmembrane permeation mechanisms and impacts the accumulation in cancer cells.
Collapse
|
32
|
Matović J, Järvinen J, Sokka IK, Imlimthan S, Raitanen JE, Montaser A, Maaheimo H, Huttunen KM, Peräniemi S, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and In Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates. Mol Pharm 2020; 18:285-304. [PMID: 33390018 DOI: 10.1021/acs.molpharmaceut.0c00917] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Boron neutron capture therapy (BNCT) is a noninvasive binary therapeutic modality applicable to the treatment of cancers. While BNCT offers a tumor-targeting selectivity that is difficult to match by other means, the last obstacles preventing the full harness of this potential come in the form of the suboptimal boron delivery strategies presently used in the clinics. To address these challenges, we have developed delivery agents that target the glucose transporter GLUT1. Here, we present the chemical synthesis of a number of ortho-carboranylmethyl-substituted glucoconjugates and the biological assessment of all positional isomers. Altogether, the study provides protocols for the synthesis and structural characterization of such glucoconjugates and insights into their essential properties, for example, cytotoxicity, GLUT1-affinity, metabolism, and boron delivery capacity. In addition to solidifying the biochemical foundations of a successful GLUT1-targeting approach to BNCT, we identify the most promising modification sites in d-glucose, which are critical in order to further develop this strategy toward clinical use.
Collapse
Affiliation(s)
- Jelena Matović
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Juulia Järvinen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Iris K Sokka
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Surachet Imlimthan
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Jan-Erik Raitanen
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Ahmed Montaser
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Hannu Maaheimo
- VTT Technical Research Centre of Finland Ltd., P.O. Box 1000, FI-02044 VTT, Finland
| | - Kristiina M Huttunen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Sirpa Peräniemi
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Anu J Airaksinen
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland.,Turku PET Centre, Department of Chemistry, University of Turku, P.O. Box 52, FI-20521 Turku, Finland
| | - Mirkka Sarparanta
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mikael P Johansson
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland.,Helsinki Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland.,CSC-IT Center for Science Ltd., P.O. Box 405, FI-02101 Espoo, Finland
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Filip S Ekholm
- Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland
| |
Collapse
|
33
|
Matović J, Järvinen J, Bland HC, Sokka IK, Imlimthan S, Ferrando RM, Huttunen KM, Timonen J, Peräniemi S, Aitio O, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Addressing the Biochemical Foundations of a Glucose-Based "Trojan Horse"-Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment. Mol Pharm 2020; 17:3885-3899. [PMID: 32787269 PMCID: PMC7539299 DOI: 10.1021/acs.molpharmaceut.0c00630] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 08/05/2020] [Accepted: 08/11/2020] [Indexed: 12/12/2022]
Abstract
Boron neutron capture therapy (BNCT) for cancer is on the rise worldwide due to recent developments of in-hospital neutron accelerators which are expected to revolutionize patient treatments. There is an urgent need for improved boron delivery agents, and herein we have focused on studying the biochemical foundations upon which a successful GLUT1-targeting strategy to BNCT could be based. By combining synthesis and molecular modeling with affinity and cytotoxicity studies, we unravel the mechanisms behind the considerable potential of appropriately designed glucoconjugates as boron delivery agents for BNCT. In addition to addressing the biochemical premises of the approach in detail, we report on a hit glucoconjugate which displays good cytocompatibility, aqueous solubility, high transporter affinity, and, crucially, an exceptional boron delivery capacity in the in vitro assessment thereby pointing toward the significant potential embedded in this approach.
Collapse
Affiliation(s)
- Jelena Matović
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Juulia Järvinen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Helena C. Bland
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Iris K. Sokka
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Surachet Imlimthan
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Ruth Mateu Ferrando
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Kristiina M. Huttunen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Juri Timonen
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Sirpa Peräniemi
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Olli Aitio
- Glykos
Finland Ltd., Viikinkaari
6, FI-00790 Helsinki, Finland
| | - Anu J. Airaksinen
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
- Turku
PET Centre, Department of Chemistry, University
of Turku, P.O. Box 52, FI-20521 Turku, Finland
| | - Mirkka Sarparanta
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| | - Mikael P. Johansson
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
- Helsinki
Institute of Sustainability Science, HELSUS, FI-00014 Helsinki, Finland
| | - Jarkko Rautio
- School
of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
| | - Filip S. Ekholm
- Department
of Chemistry, University of Helsinki, Finland, P.O. Box 55, FI-00014 Helsinki, Finland
| |
Collapse
|
34
|
Nakase I, Aoki A, Sakai Y, Hirase S, Ishimura M, Takatani-Nakase T, Hattori Y, Kirihata M. Antibody-Based Receptor Targeting Using an Fc-Binding Peptide-Dodecaborate Conjugate and Macropinocytosis Induction for Boron Neutron Capture Therapy. ACS OMEGA 2020; 5:22731-22738. [PMID: 32954120 PMCID: PMC7495456 DOI: 10.1021/acsomega.0c01377] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 08/18/2020] [Indexed: 05/19/2023]
Abstract
Boron neutron capture therapy (BNCT) is a radiation method used for cancer therapy. Cellular uptake of boron-10 (10B) atoms induces cancer cell death by the generation of alpha particles and recoiling lithium-7 (7Li) nuclei when the cells are irradiated with low-energy thermal neutrons. Current BNCT technology shows effective therapeutic benefits in refractory cancers such as brain tumors and head and neck cancers. However, improvements to cancer targeting and the cellular uptake efficacy of the boron compounds and the expansion of the diseases treatable by BNCT are highly desirable. In this research, we aimed to develop an antibody-based drug delivery method for BNCT through the use of the Z33 peptide, which shows specific recognition of and interaction with the Fc domain of human IgG, for on-demand receptor targeting. In addition, we determined with an in vitro assay that macropinocytosis induction during antibody-based drug delivery is crucial for the biological activity of BNCT.
Collapse
Affiliation(s)
- Ikuhiko Nakase
- Graduate
School of Science, Osaka Prefecture University, 1-1, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan
- NanoSquare
Research Institute, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
- . Phone: +81 722549895. Fax: +81 722549895
| | - Ayako Aoki
- Graduate
School of Science, Osaka Prefecture University, 1-1, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan
- NanoSquare
Research Institute, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
| | - Yuriko Sakai
- Research
Center of BNCT, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
| | - Shiori Hirase
- Graduate
School of Science, Osaka Prefecture University, 1-1, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan
- NanoSquare
Research Institute, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
| | - Miki Ishimura
- Research
Center of BNCT, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
| | - Tomoka Takatani-Nakase
- Department
of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, 11-68, Koshien Kyuban-cho, Nishinomiya, Hyogo 663-8179, Japan
| | - Yoshihide Hattori
- Research
Center of BNCT, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
- . Phone: +81 722546423
| | - Mitsunori Kirihata
- Research
Center of BNCT, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan
| |
Collapse
|
35
|
Boric Acid, a Lewis Acid With Unique and Unusual Properties: Formulation Implications. J Pharm Sci 2020; 109:2375-2386. [DOI: 10.1016/j.xphs.2020.04.015] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 04/05/2020] [Accepted: 04/22/2020] [Indexed: 12/16/2022]
|
36
|
Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020; 8:571. [PMID: 32733853 PMCID: PMC7359416 DOI: 10.3389/fchem.2020.00571] [Citation(s) in RCA: 132] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.
Collapse
Affiliation(s)
- Paul Hoppenz
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | | |
Collapse
|
37
|
Worm DJ, Els‐Heindl S, Beck‐Sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Pept Sci (Hoboken) 2020. [DOI: 10.1002/pep2.24171] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Dennis J. Worm
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | - Sylvia Els‐Heindl
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | | |
Collapse
|
38
|
Nelyubin AV, Klyukin IN, Zhdanov AP, Zhizhin KY, Kuznetsov NT. Synthesis of 1-Naphtylnitrilium closo-Decaborate and Amino Acid Conjugates and Their Photophysical Properties. RUSS J INORG CHEM+ 2020. [DOI: 10.1134/s0036023619140043] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
39
|
|
40
|
Nomoto T, Inoue Y, Yao Y, Suzuki M, Kanamori K, Takemoto H, Matsui M, Tomoda K, Nishiyama N. Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism. SCIENCE ADVANCES 2020; 6:eaaz1722. [PMID: 32010792 PMCID: PMC6976296 DOI: 10.1126/sciadv.aaz1722] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 11/25/2019] [Indexed: 05/10/2023]
Abstract
In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid transporters including LAT1. However, the therapeutic success of BPA has been sometimes compromised by its unfavorable efflux from cytosol due to their antiport mechanism. Here, we report that poly(vinyl alcohol) (PVA) can form complexes with BPA through reversible boronate esters in aqueous solution, and the complex termed PVA-BPA can be internalized into cancer cells through LAT1-mediated endocytosis, thereby enhancing cellular uptake and slowing the untoward efflux. In in vivo study, compared with clinically used fructose-BPA complexes, PVA-BPA exhibited efficient tumor accumulation and prolonged tumor retention with quick clearance from bloodstream and normal organs. Ultimately, PVA-BPA showed critically enhanced antitumor activity in BNCT. The facile technique proposed in this study offers an approach for drug delivery focusing on drug metabolism.
Collapse
Affiliation(s)
- Takahiro Nomoto
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
- Corresponding author. (T.N.); (N.N.)
| | - Yukiya Inoue
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Ying Yao
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Minoru Suzuki
- Division of Particle Radiation Oncology, Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Kaito Kanamori
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Hiroyasu Takemoto
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Makoto Matsui
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Keishiro Tomoda
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
| | - Nobuhiro Nishiyama
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa 226-8503, Japan
- Innovation Center of Nanomedicine, Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
- Corresponding author. (T.N.); (N.N.)
| |
Collapse
|
41
|
Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Lerchen HG, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. J Org Chem 2019; 85:1446-1457. [PMID: 31813224 DOI: 10.1021/acs.joc.9b02406] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Boron neutron capture therapy (BNCT) allows the selective elimination of malignant tumor cells without affecting healthy tissue. Although this binary radiotherapy approach has been known for decades, BNCT failed to reach the daily clinics to date. One of the reasons is the lack of selective boron delivery agents. Using boron loaded peptide conjugates, which address G protein-coupled receptors overexpressed on tumor cells allow the intracellular accumulation of boron. The gastrin-releasing peptide receptor (GRPR) is a well-known target in cancer diagnosis and can potentially be used for BNCT. Here, we present the successful introduction of multiple bis-deoxygalactosyl-carborane building blocks to the GRPR-selective ligand [d-Phe6, β-Ala11, Ala13, Nle14]Bn(6-14) (sBB2L) generating peptide conjugates with up to 80 boron atoms per molecule. Receptor activation was retained, metabolic stability was increased, and uptake into PC3 cells was proven without showing any intrinsic cytotoxicity. Furthermore, undesired uptake into liver cells was suppressed by using l-deoxygalactosyl modified carborane building blocks. Due to its high boron loading and excellent GRPR selectivity, this conjugate can be considered as a promising boron delivery agent for BNCT.
Collapse
Affiliation(s)
- Paul Hoppenz
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | | | | | - Bernd Riedl
- Bayer AG , Aprather Weg 18A , Wuppertal , Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Annette G Beck-Sickinger
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| |
Collapse
|
42
|
Li R, Zhang J, Guo J, Xu Y, Duan K, Zheng J, Wan H, Yuan Z, Chen H. Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy. Mol Pharm 2019; 17:202-211. [PMID: 31763850 DOI: 10.1021/acs.molpharmaceut.9b00898] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Boron neutron capture therapy (BNCT) has received extensive attention as noninvasive cell-level oncotherapy for treating solid cancer tumors. However, boron-containing drugs such as l-boronophenylalanine (BPA) and sodium borocaptate have low boron content and/or poor tumor-targeting ability, limiting their application. In this study, we designed and synthesized a series of nontoxic, dual-target boron carriers (B139, B142, and B151) with the ability to accumulate specifically in tumor cells. We found that the B139 uptake into hypoxic tumor regions was high, with a 70-fold boron content compared to BPA. In addition, in vivo observation showed that B139 can be trapped in tumor cells for a prolonged period and maintains an effective therapeutic concentration, with a peak boron concentration of 50.7 μg/g and a high tumor: blood boron ratio of >3, achieving ideal BNCT conditions. Cytotoxicity evaluation in mice further proved that B139 is safe and reliable. Therefore, B139 has great potential for BNCT application as a dual-target, safe, and efficient boron carrier.
Collapse
Affiliation(s)
- Ruixi Li
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Juanjuan Zhang
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Jingxuan Guo
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Yue Xu
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Kunyuan Duan
- Department of Pharmacy , Qujing Medical College , Qujing 655000 , China
| | - Jinrong Zheng
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Hao Wan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Zhenwei Yuan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Haiyan Chen
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| |
Collapse
|
43
|
Aldossari S, McMahon G, Lockyer NP, Moore KL. Microdistribution and quantification of the boron neutron capture therapy drug BPA in primary cell cultures of human glioblastoma tumour by NanoSIMS. Analyst 2019; 144:6214-6224. [PMID: 31528921 DOI: 10.1039/c9an01336a] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The ability of secondary ion mass spectrometry (SIMS) to provide high sensitivity imaging of elements and small-medium mass molecules in biological tissues and cells, makes it a very powerful tool for drug distribution studies. Here we report on the application of a high-resolution dynamic SIMS instrument for the quantification and localisation of therapeutic levels of the BNCT agent l-para-(dihydroxyboryl)-phenylalanine (BPA) in primary cell cultures from human patients exhibiting glioblastoma multiform tumours. Boron uptake and distribution was determined quantitatively as a function of cell-sampling location and different treatment regimes. Importantly, BPA was found to accumulate in cancer cells invading the 'brain around tumour' tissue in addition to the main tumour site. Pre-treatment of samples with l-tyrosine was found not to increase the uptake of BPA, nor change the intracellular drug distribution. In cultured cells from the tumour core and brain around tumour, with and without l-tyrosine pre-treatment, normalised boron-related signals were higher from cell nuclei than from cytoplasm. An efflux treatment was found to reduce BPA levels, but at a rate slower than the original uptake, and did not affect the intracellular drug distribution. To the best of our knowledge, these data represent the first published study of BPA uptake and l-amino acid pre-treatment in cultured primary human cells using dynamic SIMS, and the most detailed, subcellular distribution study of a BNCT agent in any cellular system.
Collapse
Affiliation(s)
- Samar Aldossari
- Department of Chemistry, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.
| | | | | | | |
Collapse
|
44
|
Worm DJ, Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy. J Med Chem 2019; 63:2358-2371. [PMID: 31589041 DOI: 10.1021/acs.jmedchem.9b01136] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY1R-preferring ligand [F7,P34]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY1R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agents for BNCT.
Collapse
Affiliation(s)
- Dennis J Worm
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Paul Hoppenz
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | | | - Bernd Riedl
- Bayer AG, Aprather Weg 18A, 42113 Wuppertal, Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | | |
Collapse
|
45
|
Viñas C, Núñez R, Bennour I, Teixidor F. Periphery Decorated and Core Initiated Neutral and Polyanionic Borane Large Molecules: Forthcoming and Promising Properties for Medicinal Applications. Curr Med Chem 2019; 26:5036-5076. [PMID: 31161983 DOI: 10.2174/0929867326666190603123838] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 08/13/2018] [Accepted: 08/15/2018] [Indexed: 11/22/2022]
Abstract
A mini-review based on radial growing macromolecules and core initiated Borane
periphery decorated with o-carboranes and metallacarboranes that has been developed in the
authors laboratories is reported. The review is divided into four sections; three of them are
related to the design and synthesis of these large boron-containing molecules and the fourth
deals with the unique properties of anionic metallacarborane molecules that provide a glimpse
of their potential for their promising use in medicinal applications. Their unique stability
along with their geometrical and electronic properties, as well as the precise steric structure of
1,2-closo-C2B10H12 (o-carborane) that has the potential for the incorporation of many substituents:
at the carbon (Cc), at the boron and at both carbon and boron vertices, suggests this
cluster as an innovative building block or platform for novel applications that cannot be
achieved with organic hydrocarbon compounds. Poly(aryl-ether) dendrimers grown from
fluorescent cores, such as 1,3,5-triarylbenzene or meso-porphyrins, have been decorated with
boron clusters to attain rich boron containing dendrimers. Octasilsesquioxane cubes have been
used as a core for its radial growth to get boron-rich large molecules. The unique properties of
cobaltabisdicarbollide cluster, which include: i) self-assembly in water to produce monolayer
nano-vesicles, ii) crossing lipid bilayer membranes, iii) interacting with membrane cells, iv)
facilitating its visualization within cells by Raman and fluorescence techniques and v) their
use as molecular platform for “in vivo” imaging are discussed in detail.
Collapse
Affiliation(s)
- Clara Viñas
- Institut de Ciencia de Materials de Barcelona (ICMAB-CSIC). Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Rosario Núñez
- Institut de Ciencia de Materials de Barcelona (ICMAB-CSIC). Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Ines Bennour
- Institut de Ciencia de Materials de Barcelona (ICMAB-CSIC). Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Francesc Teixidor
- Institut de Ciencia de Materials de Barcelona (ICMAB-CSIC). Campus UAB, 08193 Bellaterra, Barcelona, Spain
| |
Collapse
|
46
|
Luderer MJ, Muz B, Alhallak K, Sun J, Wasden K, Guenthner N, de la Puente P, Federico C, Azab AK. Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy. Pharm Res 2019; 36:144. [PMID: 31392417 DOI: 10.1007/s11095-019-2670-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Accepted: 07/09/2019] [Indexed: 11/26/2022]
Abstract
PURPOSE Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation requires sufficient tumor boron delivery while minimizing nonspecific accumulation. METHODS Thermal sensitive liposomes (TSLs) were designed to have a stable drug payload at physiological temperatures but engineered to have high permeability under mild hyperthermia. RESULTS We found that TSLs improved the tumor-specific delivery of boronophenylalanine (BPA) and boronated 2-nitroimidazole derivative B-381 in D54 glioma cells. Uniquely, the 2-nitroimidazole moiety extended the tumor retention of boron content compared to BPA. CONCLUSION This is the first study to show the delivery of boronated compounds using TSLs for BNCT, and these results will provide the basis of future clinical trials using TSLs for BNCT.
Collapse
Affiliation(s)
- Micah John Luderer
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Barbara Muz
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Kinan Alhallak
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Jennifer Sun
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
| | - Katherine Wasden
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Nicole Guenthner
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Pilar de la Puente
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Cinzia Federico
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA
| | - Abdel Kareem Azab
- Department of Radiation Oncology, Cancer Biology Division, Washington University School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, MO, 63108, USA.
- Department of Biomedical Engineering, Washington University, St. Louis, MO, USA.
| |
Collapse
|
47
|
Garabalino MA, Olaiz N, Portu A, Saint Martin G, Thorp SI, Pozzi ECC, Curotto P, Itoiz ME, Monti Hughes A, Colombo LL, Nigg DW, Trivillin VA, Marshall G, Schwint AE. Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:455-467. [PMID: 31123853 DOI: 10.1007/s00411-019-00796-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 05/07/2019] [Indexed: 05/17/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina.
| | - Nahuel Olaiz
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Agustina Portu
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Gisela Saint Martin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Silvia I Thorp
- Sub-gerencia Instrumentación y Control, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - María E Itoiz
- Departamento de Anatomía Patología, Facultad de Odontología, Universidad de Buenos Aires, Marcelo T. de Alvear 2142, C1122AAH, Ciudad Autónoma De Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Lucas L Colombo
- Instituto de Oncología Angel H. Roffo, Avenida San Martin 5481, C1417DTB, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID, 83402, USA
| | - Verónica A Trivillin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Guillermo Marshall
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| |
Collapse
|
48
|
KUBOTA AYANO, MATSUKAWA TAKEHISA, YANAGIE HIRONOBU, YANAGAWA MASASHI, HIRATA TAKAFUMI, SHINOHARA ATSUKO, YOKOYAMA KAZUHITO. Quantitative Bio-imaging of Gadolinium-157 in Tissues Through Laser-ablation ICP-MS for Neutron Capture Therapy. JUNTENDO IJI ZASSHI 2019. [DOI: 10.14789/jmj.2019.65.jmj19-oa12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- AYANO KUBOTA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
| | - TAKEHISA MATSUKAWA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Department of Forensic Medicine, Juntendo University Faculty of Medicine
| | - HIRONOBU YANAGIE
- Department of Nuclear Engineering and Management, The University of Tokyo
| | - MASASHI YANAGAWA
- Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine
| | | | - ATSUKO SHINOHARA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Research Institute for Cultural Studies, Seisen University
| | - KAZUHITO YOKOYAMA
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine
- Department of Epidemiology and Social Medicine, International University of Health and Welfare Graduate School of Public Health
| |
Collapse
|
49
|
Synthesis of multiple boron-containing analogs via Ugi-4CR. RESEARCH ON CHEMICAL INTERMEDIATES 2019. [DOI: 10.1007/s11164-018-3629-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
50
|
Yamagami M, Tajima T, Ishimoto K, Miyake H, Michiue H, Takaguchi Y. Physical modification of carbon nanotubes with a dendrimer bearing terminal mercaptoundecahydrododecaborates (Na
2
B
12
H
11
S). HETEROATOM CHEMISTRY 2018. [DOI: 10.1002/hc.21467] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Masahiro Yamagami
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Tomoyuki Tajima
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Kango Ishimoto
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Hideaki Miyake
- Graduate School of Sciences and Technology for InnovationYamaguchi University Yamaguchi Japan
| | | | - Yutaka Takaguchi
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| |
Collapse
|